All Stories

  1. Placental Growth Factor: New Treatment Target Bringing Hope in Hepatopulmonary Syndrome

    Article • Hepatology, January 2018, Wiley

    Mercedes Fernandez

  2. Circadian- and UPR-dependent control of CPEB4 mediates a translational response to counteract hepatic steatosis under ER stress

    Article • Nature, January 2017, Nature

    Mercedes Fernandez

  3. Sequential Functions of CPEB1 and CPEB4 Regulate Pathologic Expression of Vascular Endothelial Growth Factor and Angiogenesis in Chronic Liver Disease

    Article • Gastroenterology, April 2016, Elsevier

    Mercedes Fernandez

  4. Role and therapeutic potential of vascular stem/progenitor cells in pathological neovascularisation during chronic portal hypertension

    Article • Gut, March 2016, BMJ

    Mercedes Fernandez

  5. Molecular pathophysiology of portal hypertension

    Article • Hepatology, March 2015, Wiley

    Mercedes Fernandez

  6. Disruption of negative feedback loop between vasohibin-1 and vascular endothelial growth factor decreases portal pressure, angiogenesis, and fibrosis in cirrhotic rats

    Article • Hepatology, June 2014, Wiley

    Mercedes Fernandez

  7. Antiangiogenic and antifibrogenic activity of pigment epithelium-derived factor (PEDF) in bile duct-ligated portal hypertensive rats

    Article • Gut, May 2014, BMJ

    Mercedes Fernandez

  8. Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats

    Article • AJP Gastrointestinal and Liver Physiology, March 2012, American Physiological Society

    Mercedes Fernandez

  9. Relevance of the mTOR signaling pathway in the pathophysiology of splenomegaly in rats with chronic portal hypertension

    Article • Journal of Hepatology, April 2010, Elsevier

    Mercedes Fernandez

  10. Apelin signaling modulates splanchnic angiogenesis and portosystemic collateral vessel formation in rats with portal hypertension

    Article • Journal of Hepatology, February 2009, Elsevier

    Mercedes Fernandez

  11. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats

    Article • Hepatology, November 2008, Wiley

    Mercedes Fernandez

  12. The somatostatin analogue octreotide inhibits angiogenesis in the earliest, but not in advanced, stages of portal hypertension in rats

    Article • Journal of Cellular and Molecular Medicine, September 2008, Wiley

    Mercedes Fernandez

  13. NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats

    Article • Gut, April 2007, BMJ

    Mercedes Fernandez

  14. Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats

    Article • Hepatology, January 2007, Wiley

    Mercedes Fernandez

  15. Heme oxygenase attenuates oxidative stress and inflammation, and increases VEGF expression in portal hypertensive rats

    Article • Journal of Hepatology, June 2006, Elsevier

    Mercedes Fernandez

  16. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats

    Article • Journal of Hepatology, July 2005, Elsevier

    Mercedes Fernandez

  17. Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice

    Article • Gastroenterology, March 2004, Elsevier

    Mercedes Fernandez

  18. Vascular endothelial growth factor increases heme oxygenase-1 protein expression in the chick embryo chorioallantoic membrane

    Article • British Journal of Pharmacology, June 2003, Wiley

    Mercedes Fernandez

  19. Increased heme oxygenase-1 gene expression in liver cells and splanchnic organs from portal hypertensive rats

    Article • Hepatology, June 1999, Wiley

    Mercedes Fernandez